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Introduction
The Regence Group is a Blue Cross, Blue Shield plan in the
Paciﬁc Northwest that covers approximately two and a half
million people resident in the states of Washington, Oregon,
Idaho, and Utah. The Pharmacy Department at Regence is
responsible for reviewing all drugs that are ultimately placed on
their formulary and also for drug policy. The evolution of the use
of medication reviews in managed care plans, how evidence is
used to make formulary decisions, and the role of the Pharmacy
and Therapeutics Committee in the decision-making process, are
discussed.
Evolution of Medication Reviews
Medication reviews of evidence that inform formulary decision-
making have been utilized by health insurance organizations in
the United States for many years. Approaches to conducting
these types of reviews have evolved over time from manual
methods of assessing formulary kits and abstracts of some pub-
lished literature, to the application of sophisticated electronic
processes that facilitate the processing of huge amounts of infor-
mation and lead to a much more comprehensive assessment of
pertinent information (Fig. 1). Notably, The Regence Group was
instrumental in the early development of the Academy of
Managed Care Pharmacy dossier, a medical data source that is
currently widely used in the United States. Other tools and
sources of information include evidence tables, pharmacoeco-
nomic modeling, Food and Drug Administration (FDA) docket
material, primary and secondary literature, and practice guide-
lines from nationally recognized agencies. At The Regence
Group, we are now at the stage where best practice is not only
having evidence, but is also being consistent with how that
evidence is used. As such, the approach we take is to formulate
the key research questions in the context of the goals of a par-
ticular analysis and then apply a reproducible, systematic method
comprising a critical appraisal framework that is transparent to
the general public. Indeed, with due regard to transparency, all of
the information that we evaluate for formulary decisions is
readily available on RegenceRx.com [1].
Although drug and technology assessments are continually
being undertaken by multiple well-funded and high-quality agen-
cies that provide access directly to relevant information; such as
the Cochrane Library [2], National Institute for Health and
Clinical Excellence [3], Clinical Evidence [4], Agency for Health-
care Research and Quality [5], The Canadian Agency for Drug’s
and Technologies in Health [6] and the FDA [7], our assessment
process agenda is not necessarily aligned with the timing of
publication. This is partly because of the way information is used
in our appraisal process and partly because of time pressures
for producing formulary decisions within the US health-care
environment.
Evidence-Based Medicine Decision-Making
At The Regence Group, our best practice framework for
evidence-based medicine decision-making comprises systematic
evaluation, study data audit, critically appraising the evidence,
and compilation of best information for informing formulary
decisions in the form of a drug monograph. The systematic
evaluation starts with a predeﬁned search strategy that com-
prehensively gathers information in the form of randomized
controlled trials, meta-analyses, systematic reviews, and obser-
vational studies about relevant end points and populations. As
mentioned previously, the sources for this are myriad and can
lead to collections of hundreds of publications (Fig. 2). Critical
appraisal of the studies is done using a modiﬁcation of the Delﬁni
Group’s process (http://www.delﬁni.org/—March 21, 2010)
which typically reduces the number of publications that are
deemed reliable to, on average, about 15%, and upon which the
formulary considerations are made.
As is the case with many other managed care plans, we
simplify the information selected by the critical appraisal of the
evidence into categories of “inferior value,” “equivalent value,”
and “superior value.” Inferior value typically means that a
product may have a lesser clinical beneﬁt than existing options,
or there is some sort of a safety issue that suggests the product
may not bring any clinical beneﬁt and, in fact, may bring harms
to the patient population. Equivalent value, which comprises
about 85% of the evidence, refers to drugs that, unless there are
signiﬁcantly different clinical properties, are considered to be not
very different from existing therapies; i.e., there are already mul-
tiple similar drugs of the same class with a similar mechanism of
action. The last category, superior value, is reserved for products
that may indeed bring additional clinical beneﬁt to the armamen-
tarium of existing products.
Establishing a Systematic Review Process
The Consolidated Standards of Reporting Trials statement [8]
details 22 descriptions of informational elements that are impor-
tant in determining whether a study provides value to your
assessment. Using this as a template, we create a checklist for
each study that is identiﬁed by our search strategy. We then apply
a validity and usability grading scale based on that of the Delﬁni
Group [9] (Fig. 3). According to this scale, Grade A is a straight-
forward designation of utility; Grade B encompasses a high and
a low category accommodating the fact that the evidence may be
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potentially strong and therefore might be sufﬁcient in making
useful health-care decisions. Then there are Grades U and Grade
X that encompass uncertainty and lack of utility; information in
these grades is typically not considered by the Pharmacy and
Therapeutics Committee. In addition to assigning a grade to the
evidence, for added transparency, we also prepare a critique that
summarizes our ﬁndings based on the critical literature review
for each of the studies. This will have the salient points for the
physicians on the committee to use to decide whether or not they
will consider the evidence in making the ultimate formulary
decision.
Reasons for Excluding Data
There are many reasons why studies end up being considered
unreliable sources of evidence:
• lack of transparency of methodologies including random-
ization, allocation, and blinding methods;
• large numbers lost to follow-up;
• problematic choices of outcomes rendering the data mean-
ingless to the population of a managed care organization;
• lack of intent to treat analysis;
• nonsigniﬁcant ﬁndings from underpowered studies;
• post hoc analyses
By way of example, if we consider 24 randomized controlled
trials, including a total of approximately 8000 patients, that
examined the efﬁcacy of a new medication for the treatment of
seizures, nerve pain, ﬁbromyalgia and anxiety, we ﬁnd that the
reported study conclusions are that the drug is effective for
treating these conditions compared to placebo. Nevertheless,
when we subject these trials to our critical appraisal process, we
produce somewhat different conclusions (Fig. 4). Indeed, on
assessing the quality of the data it appears there is only poten-
tially useful information for this particular drug from one trial.
So, our conclusions are somewhat different from the study
authors in that although we did ﬁnd evidence of treatment value
Figure 1 Evolution of medication reviews.
Figure 2 Systematic evaluation for evidence-
based decision-making in medicine.
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over placebo for seizures, there was uncertainty in the evidence
about its value in the treatment of the other conditions. Further-
more, it remains unknown whether or not this drug is any better
than existing drugs for this indication.
Taking the treatment of ﬁbromyalgia as a speciﬁc example,
there are multiple trials of four existing drugs used to treat this
condition (milnacipran, duloxetine, pregabalin, gabapentin),
with the number of patients ever randomized to these treatments
ranging from 150 to more than 2500. Using our critical appraisal
criteria, we found none of the available evidence from these trials
to be even possibly useful; indeed, there was uncertainty in all
cases, with no data really demonstrating superiority of one over
another and modest beneﬁt, at most, among medications for
reducing ﬁbromyalgia pain symptoms.
Although we now apply equal rigor to all drug evaluations in
all disease areas, it is worth noting that historically, the same
rigor of appraisal was not usually applied to cancer drugs, which
were generally automatically added to the drug formulary.
Taking sorafenib as a current example, we were able to ﬁnd
reliable evidence of efﬁcacy in the treatment of unresectable
hepatocellular carcinoma in that it improved survival for about 3
months, compared to placebo. In this case, this was considered
sufﬁcient to have the drug placed on our formulary.
Pharmacoeconomic Data
From a practical standpoint, we would like to use pharmacoeco-
nomic data in the review process; however, if there is no useful
clinical evidence to guide a decision, then we will typically not
use these data at all. This is based on the philosophy that before
you can use a pharmacoeconomic model to support outcomes
and/or cost savings, the model itself needs to be based on sound,
reliable scientiﬁc data as its foundation. Areas where we have
been able to utilize pharmacoeconomic data, such as that for
Grade A: Useful – The evidence is strong and appears sufficient to use in making health care 
decisions; it is both valid and useful.
Grade “High to Low B”: Possibly Useful - The evidence is potentially strong and might be sufficient to
use in making health care decisions. 
- High B: Evidence is strong enough to conclude that results are probably valid and useful; however,
study results from multiple studies are inconsistent, or studies may have some (but not lethal) threats to
validity.
- Low B: Evidence might be sufficient to use in making health care decisions; however, there remains
sufficient uncertainty that evidence cannot fully reach a high Grade B and uncertainty is not great enough to 
fully warrant a Grade U. 
Grade U: Uncertain – There is sufficient uncertainty so that caution is urged regarding the use 
of the information in making health care decisions.
- Grade UV:
- Grade UU:
- Grade UVU:
- Grade UA:
Uncertain Validity – perceived methodological weaknesses
Uncertain Usefulness - methodology appropriate but applicability of results uncertain 
Uncertain Validity and Usefulness – combination of the above
Uncertainty of Author – author uncertain about findings
Grade X: Not Useful - studies are so poorly done and are so potentially misleading that the
strongest caution is urged about their quality 
Grade U and X evidence is not considered by P&T Committee. 
Figure 3 Grading of evidence: Modiﬁed Delﬁni
Validity & Usability Grading Scale [9].
Figure 4 Critical appraisal of scientiﬁc evidence.
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different osteoporosis agents and ACE inhibitors, have contrib-
uted to our making of sound formulary decisions, because we
acknowledge that there is reliable evidence that these medica-
tions provide positive outcomes (i.e., reduced fractures,
decreased heart attacks).
Observational Studies and Real-World Data
Postmarketing observational studies are very important for us, as
they help identify potential safety concerns within the local
patient population of interest. A frequent limitation of these
studies, however, is their inability to draw reliable cause and
effect conclusions. These studies would generally not hold up to
the rigors of critical appraisal, but allow insight as to where
further clinical study may be needed to prove a medication’s
value.
We have real-world pharmacy and medical data available
within our organization, and these data represent the entirety of
the real-world information that we access. This source provides
us with information about patient adherence to medication regi-
mens, expected outcomes, and appropriate medication use. In the
latter case, we can set our medication use policy and then
monitor it to establish if the medications are being used within
the bounds of our practice standards and within the bounds of
conditions where there is reliable evidence for their value to the
medical plan. Other questions we can address with these data
include whether or not medications provide medical cost offsets,
and/or quality of life and productivity beneﬁts.
Closing Remarks
The Pharmacy and Therapeutics Committee members are the
stewards of the health-care dollar and they need to have an
evidence-based philosophy in conducting their meetings and
making decisions; clearly, it is important that the committee
aligns in this way within the organization. Toward achieving this,
all of the committee members are trained in evidence-based
evaluation, so that when they receive the drug monographs, they
are well able to understand the information as it is presented.
Although 85% of the time the decisions are evidence-based, it is
worth noting that the physicians in this committee will at times
make decisions based on judgment rather than evidence. Inter-
estingly, over the past 5 years, 8 out of 10 of the evidence-based
decisions were to reject adding the drug to the formulary,
whereas in instances where the decisions were based on judg-
ment, the drugs were added to the formulary 9 times out of 10.
An indicator of the robustness of our system is seen when we
look at drugs that were withdrawn from the market in the United
States, in the last decade, because of safety problems (rofecoxib,
alosetron, valdecoxib, geﬁtinib, hydromorphine ER, inhaled
insulin, tegaserod, efalizumab) and ﬁnd that none of these drugs
was added to our formulary before withdrawal. This further
emphasizes the important role of the use of evidence in the
decision-making process and the importance of transparency of
decisions.
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